Table 2. Overview of high-risk studies 1


Study: Carey(39)
Factor-PTD <37 weeks, placebo: 23%
Factor-GA (wk) at treatment: 16-23
Factor-Treatment: Oral metronidazole 2 g, repeat @ 48 hr
Factor-Second treatment: All, 24-29 wk

Study: McDonald(38)
Factor-PTD <37 weeks, placebo: 35%
Factor-GA (wk) at treatment: 24
Factor-Treatment: Oral metronidazole 400 bid, 2 d
Factor-Second treatment: If positive test, 4 wk post-treatment

Study: Hauth(37)
Factor-PTD <37 weeks, placebo: 57%
Factor-GA (wk) at treatment: 22-24
Factor-Treatment: Oral metronidazole 250 mg tid, 7 days, plus oral erythromycin 333 mg tid, 14 d
Factor-Second treatment: If positive test, at 28 wk

Study: Morales(36)
Factor-PTD <37 weeks, placebo: 39%
Factor-GA (wk) at treatment: 13-20
Factor-Treatment: Oral metronidazole 250 mg tid, 7 d
Factor-Second treatment: No second treatment

Study: Vermuelen(35)
Factor-PTD <37 weeks, placebo:
Factor-GA (wk) at treatment: 26
Factor-Treatment: Clindamycin 2% vaginal cream daily, 7 d
Factor-Second treatment: All, 32 wk


[1]PTD, preterm delivery; GA, gestational age.


Return to Document